Clinical trial

Alzheimer's Tau Platform: Regimen A - AADvac1

NCT07167966

StatusENROLLING_BY_INVITATION

Study typeINTERVENTIONAL

Start date2026-11-03

PhasePHASE2

Study timeline

Study start (estimated)2026-11-03Date precision: day

Registry last updated2026-09-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Preclinical Alzheimer's Diseaseunresolved

Prodromal Alzheimer's Diseaseunresolved

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Interventions

DonanemabDRUG · verified · RxNorm: donanemab

Sponsors & collaborators

Paul S. Aisenlead sponsor

Axon Neuroscience SEcollaborator

University of California, San Franciscocollaborator

Massachusetts General Hospitalcollaborator

Alzheimer's Therapeutic Research Institutecollaborator

Alzheimer's Clinical Trials Consortiumcollaborator

National Institute on Aging (NIA)collaborator

Mapped research locations

NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 ProvidenceRhode Island, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07167966 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.